ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Inhibrx Biosciences (INBX) pipeline and stated timing

Name in SEC filings: Inhibrx Biosciences, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
ozekibart target date (company stated)PDUFAApril 14, 20278-K ·

Source: ORION, orionbiotechai.com/company/INBX, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/INBX

Nearest upcoming stated timing: ozekibart · PDUFA target date (company stated) · April 14, 2027

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

ozekibart

Matched

PDUFA target date (company stated)April 14, 2027

Stage: PDUFASEC filing · “PDUFA) goal date”

Public float: $174,600,000 · as of · SEC filing

biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.

8-K · Filed · Last checked

Source details

Accession 0002007919-26-000044

Alert me · Calendar: same stage and window-end month (2027-04)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
ozekibartFDA decisionApril 14, 2027
“biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

ozekibartFDA decisionApril 14, 2027
“The FDA has not identified any filing review issues at this time and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.”

Filed · 8-K

Period not started

The stated period has not started yet, so there is nothing to compare.

ozekibartFDA decisionApril 14, 2027
“The FDA has not identified any filing review issues at this time and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch INBX

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for INBX. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See INBX in the calendar · Review labels and methodology

A PDUFA date is the target date by which the FDA aims to decide on a drug or biologic application.